Sydney--23 Aug--AsiaNet/InfoQuest QSV SIGNS... EDMONTON: QSV Biologics, Ltd. Edmonton, Canada, announcedthat they have signed a 2nd contract with Tissue TherapiesLimited of Brisbane, Australia. http://www.tissuetherapies.com http://www.qsvbiologics.com . GEMALTO WINS... AMSTERDAM and TAIPEI: Gemalto, a world leader in digitalsecurity, has announced that it has won a "Best Vendor PartnerAward" for its MasterCard OneSmart PayPass EMV (EuropayMasterCard Visa) Contactless Combi Cards at the MasterCard AsiaPacific, Middle East & Africa Product Forum in August 2006. http://www.gemalto.com https://www.cathaybk.com.tw/cathaybk http://www.taipeifubon.com.tw http://www.mastercardworldwide.com PLATFORM AVAILABLE... RESEARCH TRIANGLE PARK: Harris Corporation, a leading globalprovider of wireless equipment and services, announced that itsindustry-leading TRuepoint digital microwave radio platform isnow available with 32 E1 and IP interfaces. http://www.harris.com SPHINGOMAB PRODUCED... PRINCETON, N.J. and SAN DIEGO: Lpath, Inc., the first togenerate therapeutic monoclonal antibodies against bioactivelipids, and Laureate Pharma, Inc., a full-servicebiopharmaceutical development and protein production company,has announced that they have entered into an agreement toproduce recombinant Sphingomab. http://www.laureatepharma.com http://www.lpath.com PRODUCTIVITY IMPACTED... WESTMINSTER: Reed Group, Ltd. has released a groundbreakingwhite paper on the productivity impact of its return to workguidelines, The Medical Disability Advisor, Fifth Edition,internet version. http://www.ReedGroup.com http://www.rgl.net/whitepapers/quintus.aspx AXA OFFERS... ORINDA: AXA Rosenberg Group LLC has announced that it willoffer a 130/30 Limited Shorting strategy to its institutionalclients. http://www.axarosenberg.com TT CONNECTS... CHICAGO and SINGAPORE: Trading Technologies International,Inc. and Singapore Exchange Limited announced that TT willconnect its X_TRADER order-entry platform to SGX. http://www.tradingtechnologies.com http://www.sgx.com NEUREN TRIALS... SYDNEY: Neuren Pharmaceuticals has announced the detailedpharmacokinetics analysis of the Phase 2 clinical trial of itslead compound, Glypromate, for the reduction of cognitivedecline following cardiac surgery. http://www.neurenpharma.com (AsiaNet is a consortium of leading news agenciesdistributing unedited, translated news releases for worldwideclients. Visit www.asianetnews.net for full-text versions.)